
    
      The dose escalation of ATG 017 with intensive safety monitoring to ensure the safety of the
      patients with solid tumors (solid tumors group) and hematological malignancies (hematological
      malignancies group) harbouring activating alterations in the RAS-MAPK pathway. Dose Expansion
      Phase will begin at the defined maximum tolerated dose (MTD) and/or biologically effective
      dose and/or other dose, in order to further evaluate the safety, tolerability and PDx of ATG
      017. Patients with solid tumors or hematological malignancies harbouring activating
      alterations in the RAS-MAPK pathway will be enrolled.
    
  